There is one clinical trial.
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat early-stage suspected or confirmed COVID-19 in patients with type 2 diabetes mellitus (T2DM) or prediabetes.
Description: Discontinuation of home isolation statusMeasure: Outcome of COVID-19 related illnesses Time: At days 0, 14, 28, and 56
Description: Hospitalization statusMeasure: Outcome of COVID-19 related illnesses Time: At days 0, 14, 28, and 56
Description: DeathsMeasure: Outcome of COVID-19 related illnesses Time: At days 0, 14, 28, and 56
Description: All vital signs are within the normal range for at least 24 h, including body temperature 36.5-37.5°C (97.7-99.5°F), pulse rate <90/min, respiratory rate 12-16/min and oxygen saturation level at 95-100%Measure: Proportion of participants who have complete resolution of all objective symptoms Time: At days 0, 14, 28, and 56
Description: Absence of all COVID-19-like symptoms listed by CDC (updated May 13, 2020) for at least 24 h, including fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting and diarrheaMeasure: Proportion of participants who have complete resolution of subjective symptoms Time: At days 0, 14, 28, and 56
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports